GlassScriptPhysician profile
Eric C Disbrow
NPI 1730150897
$580.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $141 · 2021: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $122.46 | 2019-2021 | |
| Abbott Laboratories | $108.64 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $50.71 | 2021 | |
| Pfizer INC. | $34.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.80 | 2019-2020 | |
| Allergan, INC. | $28.03 | 2020 | |
| Sanofi Pasteur INC. | $20.98 | 2021 | |
| Lilly USA, LLC | $19.74 | 2021 | |
| Merck Sharp & Dohme LLC | $17.09 | 2020 | |
| Acadia Pharmaceuticals INC | $16.97 | 2019 | |
| Abbvie INC. | $16.91 | 2021 | |
| Philips North America LLC | $16.39 | 2019 | |
| Amgen INC. | $16.23 | 2019 | |
| Glaxosmithkline, LLC. | $13.97 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.21 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Disbrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.